Published in Cancer Weekly, September 4th, 1995
The first patient treated is a 53-year-old woman with advanced breast cancer. Other patients who will be treated with genetically delivered IL-12 include those who have skin tumors resulting from advanced melanoma, or head and neck cancer.
"We are excited to start this trial because pre-clinical studies suggest that IL-12 can effectively destroy tumors, even when it is given in small amounts," said Michael Lotze, M.D.,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.